Evaluation of Vepdegestrant's Impact on Midazolam Pharmacokinetics in Patients with ER+/HER2 Positive Breast Cancer

The primary objective of this study is to evaluate whether the investigational drug **Vepdegestrant** alters the pharmacokinetics of **Midazolam** in patients with **ER+/HER2 positive breast cancer**. Understanding this interaction is clinically relevant as it may influence the dosing and safety profile of Midazolam when co-administered with Vepdegestrant, potentially impacting therapeutic strategies for managing this subtype of breast cancer.

The clinical trial focuses on participants diagnosed with **ER+/HER2 positive breast cancer**. The study population comprises exclusively female subjects, with an age range spanning from 18 to 64 years. The trial does not include vulnerable populations. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the pharmacokinetic interaction between **Vepdegestrant** and **Midazolam** in patients with **ER+/HER2 positive breast cancer**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is January 23, 2024, with an anticipated end date of June 18, 2024. The trial will involve a series of study visits, beginning with an inclusion visit where participants will be screened for eligibility based on specific criteria. This initial visit will ensure that only suitable candidates are enrolled in the study.

Following the inclusion visit, participants will undergo a series of follow-up visits at predetermined intervals. These visits are crucial for monitoring the participants' health, assessing the pharmacokinetic parameters, and ensuring adherence to the study protocol. The sequence of these visits is designed to systematically collect data on the interaction between the study medications. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the study's outcomes.

The expected length of participant involvement in the trial is approximately six months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial's methodology and design are meticulously crafted to ensure the collection of reliable and valid data, contributing to the understanding of the pharmacokinetic interaction between the study drugs in the specified patient population.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 23, 2024, with an estimated completion date of June 18, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that the efficacy assessments are conducted with scientific precision and reliability. The trial's design will likely involve validated scales, laboratory tests, or patient-reported outcomes, consistent with standard practices in clinical research, although specific tools or instruments are not mentioned. The trial's objective is to provide robust data on the efficacy of the intervention under investigation, contributing to the evidence base required for potential regulatory approval and clinical application.